Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Deal Details

C/PIndustryStatusTicker(s)Issuer(s)Size(m)TranchesRegionDate
HYC
HLTH
PRCD
NEGENT
Neopharmed Gentili SpA€750
2EMEA
Mar 28, 2024
currency
EUR
size (m)
400.000
maturity
Apr 8, 2030
type
Floating
tenor
6.000
call
1
registration
144A/Reg S
benchmark
-
ranking
Sr. Secured
moody's
B3
s&p
B
fitch
B+
size description
-
re-open/tap
No
ipt
E+4450bp, 0% floor, 99.00-99.50
ipt-pxd
-
guidance
E+425-450bp, 0%, 99.50
spread
425
coupon
-
spread set
-
price
99.50000
yield
-
book size (m)
-
peak book (m)
-
x-covered
-
book attrition
-
nic
-
left lead
active leads
joint leads
passive leads
-
co-managers
-
coordinating managers
-
book size (m)
-
peak book (m)
-
x-covered
-
book attrition
-
nic
-
left lead
active leads
joint leads
passive leads
-
co-managers
-
coordinating managers
-
currency
EUR
size (m)
350.000
maturity
Apr 8, 2020
type
Fixed
tenor
6.000
call
2
registration
144A/Reg S
benchmark
DBR
ranking
Sr. Secured
moody's
B3
s&p
B
fitch
B+
size description
-
re-open/tap
No
ipt
low-mid 7s
ipt-pxd
-
guidance
7.00%-7.25%
spread
489
coupon
7.125%
spread set
-
price
100.00000
yield
7.125%
book size (m)
-
peak book (m)
-
x-covered
-
book attrition
-
nic
-
left lead
active leads
joint leads
passive leads
-
co-managers
-
coordinating managers
-
book size (m)
-
peak book (m)
-
x-covered
-
book attrition
-
nic
-
left lead
active leads
joint leads
passive leads
-
co-managers
-
coordinating managers
-
Tranche Comments
Redemption: 2025-04-08; Registration: 144A/Reg S; Comments: B&D: BNP; Redemption: 2026-04-08; Registration: 144A/Reg S; Comments: B&D: BNP;
Deal Comments
03/28/2024 Neopharmed Gentili SpA (NEGENT) EUR750m144A/Reg S fixed/floating sr sec notes 2-part. B3/B/B+ (stable/sable/stable). Via BNP (B&D)/GS jt physical books/IMI jt glocos/Banca Akros/CA/JPM/Natixis jt books. No reg rights. List Lux. NY law. Settles 04/08 (T+5). - EUR400m (from expect EUR375m, and EUR300m minimum) sr sec FRN due 04/08/30 (6y). NC1 (MWC B+50bp), then at 101, 100. Reg S ISIN: XS2797354391. IPT: E+450bp, 0%, 99.00-99.50. Px talk: E+425-450bp, 0%, 99.50. Final terms: EUR400m at E+425bp, 0% floor, at 99.50. Priced: 3mE+425bp, 0% floor, at 99.50. - EUR350m (from expected EUR375m, and EUR300m minimum) sr sec fixed-rate notes due 04/08/30 (6y). NC2 (MWC B+50bp), then at 103.563, 101.781, 100. Equity claw: 2y 40% at 107.125. Special call: 10% per year the first 2 years at 103. Reg S ISIN: XS2797353401. IPT: low-mid 7s. Px talk: 7.00%-7.25%. Final terms: EUR350m 7.125% at par. Priced: 7.125% at 100. +489bp vs DBR 0.0% 02/15/30. Did investor call at 11am UKT 03/25, Q&A sessions 03/25-27. Books closed at 12pm UKT 03/28. Reconfirms were due 2:30pm UKT 03/28. UOP: repay the existing EUR700m unitranche notes, and EUR24m for cash on the B/S. Equity sponsors: Ardian and NB Renaissance. Biz: a leading primary care pharmaceutical company in Italy that promotes a well-established and diversified portfolio of leading branded off-patent products. HQ: Milan, Italy.

Commentary

Explore all other Commentary & Deal Flow

Deal Flow

Explore all other Commentary & Deal Flow
We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.